Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224789 | 0.90 | BTK (0.82) | BTKCLK2 | |
| SCHEMBL708509 | 0.90 | BTK (0.85) | BTKCLK2 | |
| SCHEMBL709929 | 0.90 | BTK (0.69) | BTKCLK2 | |
| SCHEMBL1725889 | 0.90 | BTK (1.00) | BTKCLK2 | |
| SCHEMBL708014 | 0.89 | BTK (0.85) | BTKCLK2 | |
| SCHEMBL15577291 | 0.89 | BTK (0.81) | BTKCLK2 | |
| SCHEMBL13154174 | 0.85 | BTK (0.73) | BTKCLK2 | |
| SCHEMBL707851 | 0.85 | BTK (0.80) | BTKCLK2 | |
| SCHEMBL708171 | 0.84 | BTK (0.85) | BTK | |
| SCHEMBL709879 | 0.84 | BTK (0.89) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902194-B2 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto (US) | 2011-03-08 | — | — | US | claimed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | claimed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-9993460-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-06-12 | — | — | US | disclosed |
| EP-2297142-A1 | NOVEL SUBSTITUTED PYRIDIN-2-ONES AND PYRIDAZIN-3-ONES | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-7902194-B2 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902194-B2 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902194-B2 | Inhibitors of bruton's tyrosine kinase | Roche Palo Alto (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2009156284-A1 | NOVEL SUBSTITUTED PYRIDIN-2-ONES AND PYRIDAZIN-3-ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156284-A1 | NOVEL SUBSTITUTED PYRIDIN-2-ONES AND PYRIDAZIN-3-ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | BTK 1276/4885CLK2 3341/4885 |
| US-20090318448-A1 | 7-Dimethylamino-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-3H-quinazolin-4-one; asthma ; inhibit Btk | BTK, LCK, SYK | BTK 1/4885CLK2 946/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | BTK 2508/4885CLK2 4397/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | BTK 1276/4885CLK2 3341/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | BTK 2508/4885CLK2 4397/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | BTK 2478/4885CLK2 4520/4885 |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | BTK 1276/4885CLK2 3341/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | BTK 2478/4885CLK2 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.